How Is Regenerative Medicine Used Today?

Regenerative medicine has moved from a largely experimental area of science into a field that now includes some established medical treatments, while many other approaches remain under clinical investigation.

The term “regenerative medicine” covers a wide range of technologies and therapies designed to repair, replace, or restore damaged cells, tissues, or biological functions. These approaches can involve stem cells, other types of cell therapy, tissue engineering, biomaterials, biologics, and gene-based technologies.

That broad definition is important because regenerative medicine is not one treatment, and not every therapy marketed as “regenerative” has the same level of evidence or regulatory approval.

What Is Regenerative Medicine?

The goal of regenerative medicine is to develop ways to repair or replace damaged cells, tissues, or organs and, in some cases, restore biological function. The field combines areas of medicine, biology, engineering, and materials science.

Regenerative medicine can include cell-based therapies, engineered biomaterials, tissue engineering, and gene editing. Some approaches are already being used in clinical care, while others are still being evaluated in research and clinical trials.

This means the phrase “regenerative medicine” can describe very different types of treatment. A gene therapy approved for a specific genetic disorder is very different from an experimental cell-based treatment being studied for tissue repair.

What Does Regenerative Medicine Include?

• Cell-Based Therapies

Cell-based therapies use living cells as part of a treatment. Depending on the therapy, cells may be collected from the patient or obtained from another source and then processed or modified for a specific medical purpose.

The FDA currently maintains a list of approved cellular and gene therapy products, including therapies involving hematopoietic stem cells, immune cells, genetically modified cells, and other cellular products.

Some of these treatments are used for specific cancers, blood disorders, genetic diseases, and other serious conditions.

• Stem Cell-Based Therapies

Stem cells have the ability to develop into specialized cell types, which makes them an important area of regenerative medicine research.

One established example is the use of blood-forming stem cells in certain blood and immune system disorders. Other stem cell approaches are being investigated for conditions involving damaged tissues and organs.

Researchers are also exploring ways to reprogram existing adult cells into different functional cell types. Current NIH regenerative medicine research includes work involving adult stem cells, bone repair, tissue regeneration, and gene therapy.

• Tissue Engineering

Tissue engineering combines cells, scaffolds, and biologically active materials to create or support functional tissue.

The idea is relatively straightforward: provide the cells with an environment that can help support tissue formation or repair. Researchers have explored engineered skin, cartilage, blood vessels, and other tissues.

Some engineered tissue products are already used in medicine, although the broader field of tissue engineering remains limited compared with conventional medical treatments. More complex tissues and organs continue to present significant scientific and technical challenges.

NIH's overview of tissue engineering and regenerative medicine describes how researchers use scaffolds, cells, and biological signals to develop functional tissues.

• Gene-Based Therapies

Gene therapy is another important part of the regenerative medicine landscape. Rather than introducing replacement tissue directly, some therapies work by modifying or manipulating genetic material or the biological properties of cells.

This is no longer purely theoretical. The FDA has approved a growing number of cellular and gene therapies, including treatments for certain inherited disorders, cancers, and other serious diseases.

In 2026, for example, the FDA approved Kresladi, a gene therapy for pediatric patients with severe leukocyte adhesion deficiency type I. The same year, the FDA approved Otarmeni, a gene therapy for certain patients with genetically confirmed hearing loss.

These examples illustrate how regenerative and cell-based medicine can involve highly specialized therapies developed for specific diseases rather than a single treatment that applies broadly to everyone.

Where Is Regenerative Medicine Already Being Used?

Regenerative medicine is already part of medical care in several areas, particularly in hematology, oncology, and the treatment of certain inherited conditions.

The FDA's current list of approved cellular and gene therapies includes products used for conditions such as certain blood cancers, inherited blood disorders, genetic diseases, and other serious medical conditions. Some therapies use a patient's own cells, while others use donor cells or genetically modified cells.

The field is also expanding into areas such as engineered tissues and specialized biological products. FDA-regulated cellular and gene therapies continue to advance through research and clinical development.

The important distinction is that an approved regenerative medicine therapy is approved for a specific product and specific medical indication. That does not mean every use of that type of cell, tissue, or biological material has been established as safe and effective.

What Is Still Being Researched?

A significant portion of regenerative medicine remains in the research and development stage.

Researchers are studying whether regenerative approaches can help repair tissues affected by injury, disease, aging, or treatment-related damage. Areas of investigation include bone, cartilage, muscle, skin, nerves, blood vessels, organs, and other tissues.

Current NIH regenerative medicine research includes efforts to use adult stem cells for tissue repair, develop methods for reprogramming cells, use biomaterials to support bone repair, and investigate gene therapy for salivary gland damage following radiation treatment.

These approaches may eventually lead to additional treatments, but research status matters. A promising laboratory result or an ongoing clinical trial does not mean a treatment has been proven effective or approved for routine medical use.

What About Exosomes and Other Regenerative Products?

Exosomes and other biological products are frequently discussed alongside regenerative medicine, particularly in wellness and longevity settings.

However, the fact that a product is described as “regenerative” does not establish that it is FDA-approved or that its benefits have been demonstrated for a particular condition.

The FDA continues to warn consumers about unapproved products made from human cells or tissues. The agency has reported serious adverse events associated with some unapproved products and advises consumers to be cautious about products marketed to treat or cure a wide range of diseases.

This is especially important when considering products marketed as stem cell, exosome, placental tissue, amniotic, or other human-cell or tissue-based treatments. The specific product, intended use, evidence, manufacturing process, and regulatory status all matter.

Are Regenerative Medicine Treatments FDA-Approved?

Some are.

The FDA maintains a current list of licensed cellular and gene therapy products. The list includes a wide range of products, from cell-based cancer treatments to gene therapies and engineered tissue products.

But FDA approval applies to a specific product for specific indications. It should not be interpreted as approval of every treatment that uses a similar type of cell, tissue, or biological material.

This distinction is particularly important in the regenerative medicine space because some products are marketed outside of established medical indications or without FDA approval.

What Should You Ask Before Considering a Regenerative Treatment?

If you are considering a regenerative medicine treatment, it is worth asking specific questions rather than relying on the treatment's marketing name.

Consider asking:

• What exactly is the treatment or biological product?

• What condition is it intended to treat?

• Is it FDA-approved for this specific use?

• What evidence supports its use for my condition?

• Is the treatment part of a clinical trial?

• What are the known risks and potential side effects?

• Where do the cells, tissues, or biological materials come from?

• How is the product processed and tested?

• What alternatives are available?

• How will my response be monitored?

A treatment being offered by a medical professional does not automatically mean that it is FDA-approved for the use being promoted. Understanding the distinction between an approved therapy, an investigational treatment, and an unapproved product can help you make a more informed decision.

A Personalized Approach to Regenerative Medicine

Regenerative medicine is one of the most rapidly developing areas of modern healthcare, but it is also an area where terminology can easily become broader than the evidence.

Some regenerative therapies are already part of conventional medical care. Others are being studied in clinical trials, and some products marketed as regenerative treatments remain unapproved or lack sufficient evidence for particular uses.

The most useful question is not simply whether something is called “regenerative medicine.” It is what the specific treatment is, what it is intended to do, what evidence supports it, and whether it is appropriate for the individual patient.

As the field continues to develop, personalized evaluation and careful clinical decision-making can help determine whether a regenerative approach has a meaningful role in someone's overall healthcare plan.